Lyka Labs Ltd (LYKALABS)

₹115.85▲0.81%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Lyka Labs Ltd share Performance

₹114.05
₹118
₹115.85
1.55%
Low
Day's Volatility:3.41%
High
1.86%
₹88.5
₹144.3
₹115.85
23.61%
Low
52 Weeks Volatility:48.17%
High
24.56%

Returns %
1 Month Return	-8.71 %
3 Month Return	-8.18 %
1 Year Return	+ 20.04 %

Market Stats
Previous Close	₹₹116.80
Open	₹₹115.50
Volume	₹36.59K
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹386.49Cr

Company Information

Lyka Labs, a bulk drug company, has been in the business of offering lifesaving antibiotics and treating minor infections for over three decades. Over the years, the company has also diversified into marketing medical and diagnostic machinery and equipment, ayurvedic and animal health care products, tropical steroids, anticancer products, cardiovascular drugs, and anti-inflammatory products. In the year 1991 they received a Certificate of Merit for their impressive export performance and an award from CHEMEXCIL. Two years later, their Administrative Office and Plant at Tarapur was awarded the ISO 9002 certification for its quality management system. As part of its diversification, the company had also invested in Relic Finance and acquired 26.70% of the company's paid-up equity capital through a public offer. They also launched India's first Glutathione Injection formulation during 2012-13 to become one of India's leading healthcare and pharmaceutical companies.

Share Price: ₹115.85 per share as on 21 May, 2024 04:01 PM
Market Capitalisation: ₹386.49Cr as of today
Revenue: ₹32.56Cr as on December 2023 (Q4 23)
Net Profit: ₹1.78Cr as on December 2023 (Q4 23)
Listing date: 09 Feb, 1995
Chairperson Name: KUNAL NARENDRA GANDHI

Organisation	Lyka Labs Ltd
Headquarters	Mumbai
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for Lyka Labs Ltd

Lyka Labs Ltd's High P/S Ratio May Be a Risk for Investors - 10 Apr, 2024
Lyka Labs Limited has a P/S ratio of 4.2x, higher than the industry average of 2.6x. The company's revenue growth rates are similar to the industry's expected growth rates, and investors may be paying too much for the stock if growth does not improve.

Fundamentals of Lyka Labs Ltd

Insights on Lyka Labs Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 5 quarters, 18.88 Cr → 33.11 Cr (in ₹), with an average increase of 12.9% per quarter
POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 54.81% to 58.10% in Apr 2024 quarter
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 5 quarters, -10.42 Cr → 1.78 Cr (in ₹), with an average increase of 178.5% per quarter
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 118.1% return, outperforming this stock by 98.0%
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 121.9% return, outperforming this stock by 28.5%
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 44.13% to 40.92% in Apr 2024 quarter
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 0.17% to 0.16% in Apr 2024 quarter
NEGATIVE IMPACT
Price Dip
In the last 1 month, LYKALABS stock has moved down by -8.7%